TY - JOUR
T1 - Chronic thromboembolic pulmonary hypertension
T2 - anticoagulation and beyond
AU - Martin, Karlyn A.
AU - Cuttica, Michael J.
N1 - Funding Information:
Karlyn A. Martin reports funding from Janssen Scientific Affairs for an investigator-initiated study outside the submitted work. Michael J. Cuttica reports grants and consulting fees from Bayer, United Therapeutics, and Actelion.
Publisher Copyright:
© 2021 by The American Society of Hematology
PY - 2021/12/10
Y1 - 2021/12/10
N2 - Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication in pulmonary embolism (PE) survivors, characterized by chronic vascular occlusion and pulmonary hypertension. The identification and diagnosis of CTEPH requires a stepwise approach, starting with symptom evaluation, functional evaluation, screening imaging, and progressing to interventional hemodynamic assessment. On the backbone of anticoagulation, CTEPH management necessitates a multidisciplinary approach. Surgical pulmonary thromboendarterectomy (PTE) is the only potentially curative option. In nonoperable disease or residual disease after PTE, interventional balloon pulmonary angioplasty and/or pulmonary-vasodilator therapies can be offered, in collaboration with interventional and vascular pulmonary colleagues. As it is a disease that can cause high morbidity and mortality, CTEPH requires a high index of suspicion to diagnose and treat in patients following PE.
AB - Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication in pulmonary embolism (PE) survivors, characterized by chronic vascular occlusion and pulmonary hypertension. The identification and diagnosis of CTEPH requires a stepwise approach, starting with symptom evaluation, functional evaluation, screening imaging, and progressing to interventional hemodynamic assessment. On the backbone of anticoagulation, CTEPH management necessitates a multidisciplinary approach. Surgical pulmonary thromboendarterectomy (PTE) is the only potentially curative option. In nonoperable disease or residual disease after PTE, interventional balloon pulmonary angioplasty and/or pulmonary-vasodilator therapies can be offered, in collaboration with interventional and vascular pulmonary colleagues. As it is a disease that can cause high morbidity and mortality, CTEPH requires a high index of suspicion to diagnose and treat in patients following PE.
UR - http://www.scopus.com/inward/record.url?scp=85122450873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122450873&partnerID=8YFLogxK
U2 - 10.1182/hematology.2021000282
DO - 10.1182/hematology.2021000282
M3 - Article
C2 - 34889396
AN - SCOPUS:85122450873
SN - 1520-4391
VL - 2021
SP - 478
EP - 484
JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
IS - 1
ER -